Should I buy Exelixis (EXEL) stock or is it too late?

Exelixis · Health Care · price $55

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: HC Wainwright & Co. — 70% of its targets hit on this sector (238 calls tested). It aims for $56 (+1.3 %), call made on July 3, 2026, maturing on July 3, 2027 (56 d ago).

The 6 reliable analysts $51.50-6.8 %

The 5 other firms $54-2.3 %

How to read it: the 6 reliable firms are not filtered by optimism — 1 aim above the price, 5 below, hence their $51.50 median. “The 5 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Exelixis

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
JMP Securities	100 %	+34.6 %	20	$50 -10%
Guggenheim	100 %	+29.6 %	8	$45 -19%
RBC Capital	83 %	+24.5 %	12	$46 -17%
Morgan Stanley	80 %	+23.0 %	5	$53 -4%
Truist Securities	89 %	+22.5 %	9	$52 -6%
HC Wainwright & Co.	79 %	+22.3 %	14	$56 +1%
EF Hutton	100 %	+24.8 %	7	—
Oppenheimer	56 %	+5.6 %	9	—

In short — Should you invest in Exelixis? Is it too late, still worth it? Analysts are split (27% buy, median target $52, i.e. -6%). But it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

Few solid positives from analysts right now: of 11 ratings, only 3 buys, and the median price target ($52) is -6% below the price ($55). Caution prevails.

⚠️ Reasons to hesitate

Even the most reliable firm on EXEL, TD Cowen (100% hit rate, 2 scored calls), only targets $55 (call made on May 6, 2026, maturing on May 6, 2027) (+0%) in its most recent call, and $51 (call made on November 5, 2025, maturing on November 5, 2026) (-8%) in the one coming due soonest. The stock may already have run past its target.
The consensus is not unanimous: of 11 ratings, 8 are neutral.
Limited upside: the median target is only -6% from the current price.
A 12-month target is not a guaranteed path: the price can fall in the meantime.
No dividend: your return depends only on price appreciation.

The analyst consensus on EXEL

Median target $52 (-6%) · 11 ratings · Hold consensus

Strong Buy00%

Buy327%

Hold873%

Sell00%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Exelixis now?

We won't decide for you. The facts: 27% of analysts rate it a buy, median target $52 (-6%), and TD Cowen (most reliable on EXEL, 100%) targets $55. Weigh that against valuation. This is not personalized advice.

Is it too late to invest in Exelixis?

The stated upside is small: the median target ($52) sits just -6% from the price ($55) (most reliable on EXEL: TD Cowen, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Exelixis still worth investing in?

It depends on the gap between the price ($55) and its estimated value: analysts target $52 on median (-6%), with 27% buys (most reliable on EXEL: TD Cowen, 100%). Cross-check with their real reliability on EXEL and the cautions above. Information, not advice.

What's the main risk in buying EXEL?

Even the most reliable firm on EXEL, TD Cowen (100% hit rate, 2 scored calls), only targets $55 (call made on May 6, 2026, maturing on May 6, 2027) (+0%) in its most recent call, and $51 (call made on November 5, 2025, maturing on November 5, 2026) (-8%) in the one coming due soonest. The stock may already have run past its target.

→ Go deeper: the full Exelixis profile (consensus, analyst reliability, price target, performance).